Search

Tislelizumab, a humanized immunoglobulin G4 monoclonal antibody, is a programmed cell death protein 1 (PD-1) inhibitor designed to minimize Fc gamma receptor binding on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The pharmacokinetic (PK) profile of tislelizumab was analyzed with population PK modeling using 14,473 observed serum concentration data points from 2596 cancer patients who received intravenous (i.v.) tislelizumab at 0.5-10 mg/kg every 2 weeks or every 3 weeks (q3w), or a 200 mg i.v. flat dose q3w in 12 clinical studies. Tislelizumab exhibited linear PK across the dose range tested. Baseline body weight, albumin, tumor size, tumor type, and presence of antidrug antibodies were identified as significant covariates on central clearance, whereas baseline body weight, sex, and age significantly affected central volume of distribution. Sensitivity analysis showed that these covariates did not have clinically relevant effects on tislelizumab PK. Other covariates evaluated, including race (Asian vs. White), lactate dehydrogenase, estimated glomerular filtration rate, renal function categories, hepatic function measures and categories, Eastern Cooperative Oncology Group performance status, therapy (monotherapy vs. combination therapy), and line of therapy did not show a statistically significant impact on tislelizumab PK. These results support the use of tislelizumab 200 mg i.v. q3w without dose adjustment in a variety of patient subpopulations.

A green supply chain economy considering environmental, social, and governance (ESG) factors improves the chances of functional growth through minimal risk factors. The implication of sophisticated technologies such as the Industrial Internet of Things (IIoT) and the blockchain improves the optimization and evaluation of ESG performance. An IIoT-Blockchain-based Supply Chain Economy Evaluation (IB-SCEE) model is introduced to identify and reduce functional growth risk factors. The proposed model uses green blockchain technology to identify distinct transactions’ economic demands and supply distribution. The flaws and demands in the circular economy process are validated using the IIoT forecast systems relying on ESG convenience. The minimal and maximum risks are identified based on economic and distribution outcomes. The present investigation highlights the significance of ongoing ESG-conceptualized research into blockchain-based supply chain economics. Companies who recognize the blockchain’s potential can improve corporate governance, environmental impact, and social good by increasing transparency, traceability, and accountability. A more sustainable and responsible future for global supply chains can be shaped through further research and development in this field, which will make a substantial contribution to the scientific world. This information is individually held in the green blockchain for individual risk factor analysis. The proposed model improves the recommendation and evaluation rate and reduces the risk factors with controlled evaluation time.

This study was to explore the mechanism by how exosomes (exo) derived from BMSCs affects cardiomyocyte apoptosis. BMSCs were isolated and incubated with cardiomyocytes while the cardiomyocytes were exposed to sevoflurane or DMSO treatment. Apoptotic cells were calculated and level of apoptosis related proteins was detected by Western blot. Through transfection with microRNA-(miRNA)-312 inhibitor, we evaluated the effect of BMSC-exo on the sevoflurane-induced apoptosis. Sevoflurane significantly inhibited the viability of cardiomyocytes and induced cardiomyocyte apoptosis. Besides, sevoflurane decreased the expression of miR-312 and enhanced Bax expression in cardiomyocytes through restraining the phosphorylation of MAPK/ERK. Treatment with BMSC-exo, however, activated MAPK/ERK signaling by up-regulating miR-312, thereby inhibiting cardiomyocyte apoptosis, promoting cardiomyocyte proliferation, and elevating the level of Bcl-2. In conclusion, BMSC-exo-derived miR-312 inhibits sevoflurane-induced cardiomyocyte apoptosis by activating PI3K/AKT signaling pathway.

Purpose A population pharmacokinetic (PK) analysis of the anti-fibroblast growth factor receptor 2b antibody, bemarituzumab, was performed to evaluate the impact of covariates on the PK and assess whether dose adjustment is necessary for a future phase 3 trial. Methods Serum concentration data were obtained from three clinical trials, with 1552 bemarituzumab serum samples from 173 patients, and were analyzed using nonlinear mixed-effects modeling. Results A two-compartment model with parallel linear and nonlinear (Michaelis–Menten) elimination from the central compartment best described the bemarituzumab serum concentration data. The final model estimated a typical linear clearance (CL) of 0.311 L/day, volume of distribution in the central compartment (Vc) of 3.58 L, distribution clearance (Q) of 0.952 L/day, volume of distribution in the peripheral compartment (Vp) of 2.71 L, maximum drug elimination by nonlinear clearance (Vmax) of 2.80 μg/day, and Michaelis–Menten constant (Km) of 4.45 μg/mL. Baseline body weight, baseline albumin, gender, and chemotherapy were identified as statistically significant covariates on the PK of bemarituzumab. Given the low interindividual variability of bemarituzumab key PK parameters (CL and Vc) and the small or modest effect of all statistically significant covariates on bemarituzumab exposure at steady-state, no covariate is expected to have clinically meaningful effects on bemarituzumab exposure. Conclusion No covariate had a clinically meaningful impact on bemarituzumab exposure. These results indicate that dose adjustment of bemarituzumab is not necessary, based on the aforementioned covariates, for a future phase 3 trial in gastric and gastroesophageal junction adenocarcinoma population with FGFR2b overexpression in combination with mFOLFOX6.

This report summarizes a totality-of-evidence approach supporting recommendation of a 320-mg total daily dose, either as 160-mg twice daily (BID) or 320-mg once daily (QD) for zanubrutinib in patients with mantle cell lymphoma. Data were derived from a phase 2 study in patients receiving 160-mg BID and a phase 1/2 study with similar response rates observed with 160-mg BID or 320-mg QD. Given the limited number of patients in the QD dose group, population pharmacokinetics and exposure-response analyses were employed to bridge the two regimens. The analyses showed that similar plasma exposure and BTK inhibition were achieved, and differences in trough concentration and maximum plasma concentration between the two regimens are unlikely to have a meaningful impact on efficacy and safety endpoints. The totality of data, including pharmacokinetic, pharmacodynamic, safety, efficacy, and exposure-response analyses, provided support for the recommended 320-mg total daily dose for the approved indication.

Ferrihydrite (Fh) has been demonstrated as an effective interfacial layer for photoanodes to achieve outstanding photoelectrochemical (PEC) performance for water oxidation reaction owing to its unique hole-storage function. However, it is unknown whether such a hole-storage layer can be used to construct highly efficient photocathodes for hydrogen evolution reaction (HER). In this work, we report Fh interfacial engineering of amorphous silicon photocathode (with nickel as HER cocatalyst) achieving a photocurrent density of 15.6 mA cm-2 at 0 V vs. the reversible hydrogen electrode and a half-cell energy conversion efficiency of 4.08 % in alkaline solution, outperforming most of reported a-Si based photocathodes including multi-junction configurations integrated with noble metal cocatalysts in acid solution. Besides, the photocurrent density is maintained above 14 mA cm-2 for 175 min with 100 % Faradaic efficiency for HER in alkaline solution. Our results demonstrate a feasible approach to construct efficient photocathodes via the application of a hole-storage layer.

Background and Objective Thyroid eye disease (TED) is characterized by inflammation/expansion of orbital tissues, proptosis, and diplopia. Teprotumumab is the first US Food and Drug Administration-approved therapy for TED, administered as an initial intravenous infusion of 10 mg/kg followed by 20 mg/kg every 3 weeks for an additional seven infusions. The objective of this article is to discuss the pharmacokinetics and exposure-response profile for teprotumumab in patients with TED. Methods A population pharmacokinetic analysis was performed to characterize pharmacokinetics and select dosing in patients with TED. Exposure-response was evaluated for efficacy (proptosis response, clinical activity score categorical response, and diplopia response) and safety (hyperglycemia, muscle spasms, and hearing impairment) parameters. Results Teprotumumab pharmacokinetics was linear in patients with TED, with low systemic clearance (0.334 L/day), low volume of distribution (3.9 and 4.2 L for the central and peripheral compartment, respectively), and a long elimination half-life (19.9 days). The approved dosing regimen provided > 20 µg/mL for > 90% insulin-like growth factor 1 receptor saturation throughout the dosing interval. Model-predicted mean (± standard deviation) steady-state area under the concentration-time curve, peak, and trough concentrations in patients with TED were 131 (± 30.9) mg∙h/mL, 643 (± 130) µg/mL, and 157 (± 50.6) µg/mL, respectively. Female patients had a 15% higher steady-state peak concentration but a similar steady-state area under the concentration-time curve vs male patients. No other covariates affected teprotumumab pharmacokinetics. No meaningful correlations between teprotumumab exposures and efficacy or safety parameters were observed. Conclusions Teprotumumab pharmacokinetics was well characterized in patients with TED, and generally consistent with other IgG1 antibodies. Efficacy was consistent across the exposure range with a well-tolerated safety profile supporting the current dose regimen for patients with TED. Supplementary Information The online version contains supplementary material available at 10.1007/s40262-021-01003-3.

Three-dimensional (3D) organic-inorganic hybrid perovskites have demonstrated excellent capability in solar fuel production, while the two-dimensional (2D) counterparts are generally considered inferior candidates due to the high exciton binding energy and weak light absorption. Herein, contrary to our common understanding, we find that 2D perovskites can perform photocatalytic H2 production from HI splitting more efficiently than their 3D counterparts. We observed sharp difference between 2D perovskites crystals with organic phenylalkylammonium cations of different lengths and the 3D counterparts in their stabilization behavior in aqueous solution. Moreover, we show that the organic cations length of the 2D perovskites affects the nanostructures, optoelectronic properties, and the charge transfer process significantly, which determines the photocatalytic activity of the 2D perovskites. Among the 2D perovskites under investigation, phenylmethylammonium lead iodide with the shortest organic cations achieved the best solar-to-chemical conversion efficiency of ca. 1.57 %, which is the highest value ever reported for hybrid perovskites.

Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this analysis was to develop a population pharmacokinetic (PK) model to characterize the PKs of zanubrutinib and identify the potential impact of intrinsic and extrinsic covariates on zanubrutinib PK. Data across nine clinical studies of patients with B‐cell malignancies and data of healthy volunteers (HVs) were included in this analysis, at total daily doses ranging from 20 to 320 mg. In total, 4,925 zanubrutinib plasma samples from 632 subjects were analyzed using nonlinear mixed‐effects modeling. Zanubrutinib PKs were adequately described by a two‐compartment model with sequential zero‐order then first‐order absorption, and first‐order elimination. A time‐dependent residual error model was implemented in order to better capture the observed maximum concentration variability in subjects. Baseline alanine aminotransferase and health status (HVs or patients with B‐cell malignancies) were identified as statistically significant covariates on the PKs of zanubrutinib. These factors are unlikely to be clinically meaningful based on a sensitivity analysis. No statistically significant differences in the PKs of zanubrutinib were observed based on age, sex, race (Asian, white, and other), body weight, mild or moderate renal impairment (creatinine clearance ≥ 30 mL/minute as estimated by Cockcroft‐Gault), baseline aspartate aminotransferase, bilirubin, tumor type, or use of acid‐reducing agents (including proton pump inhibitors). These results support that no dose adjustment is considered necessary based on the aforementioned factors.

Purpose To report population pharmacokinetic (PK) analysis of the phase 1 study (FPA144-001, NCT02318329) and to select a clinical dose and schedule that will achieve an empirical target trough concentration (Ctrough) for an anti-fibroblast growth factor receptor 2b antibody, bemarituzumab. Methods Nonlinear mixed-effect modeling was used to analyse PK data. In vitro binding affinity and receptor occupancy of bemarituzumab were determined. Simulation was conducted to estimate dose and schedule to achieve an empirical target Ctrough in a phase 2 trial (FIGHT, NCT03694522) for patients receiving first-line treatment combined with modified 5-fluourouracil, oxaliplatin and leucovorin (mFOLFOX6) for gastric and gastroesophageal junction adenocarcinoma. Results Bemarituzumab PK is best described by a two-compartment model with parallel linear and nonlinear (Michaelis–Menten) elimination from the central compartment. Albumin, gender, and body weight were identified as the covariates on the linear clearance and/or volume of distribution in the central compartment, and no dose adjustment was warranted. An empirical target of bemarituzumab Ctrough of ≥ 60 µg/mL was projected to achieve > 95% receptor occupancy based on in vitro data. Fifteen mg/kg every 2 weeks, with a single dose of 7.5 mg/kg on Cycle 1 Day 8, was projected to achieve the target Ctrough on Day 15 in 98% of patients with 96% maintaining the target at steady state, which was confirmed in the FIGHT trial. Conclusion A projected dose and schedule to achieve the target Ctrough was validated in phase 1 of the FIGHT trial which supported selection of the phase 2 dose and schedule for bemarituzumab.

Controlling the interaction of polarization light with an asymmetric nanostructure such as a metal/semiconductor heterostructure provides opportunities for tuning surface plasmon excitation and near-field spatial distribution. However, light polarization effects on interfacial charge transport and the photocatalysis of plasmonic metal/semiconductor photocatalysts are unclear. Herein, we reveal the polarization dependence of plasmonic charge separation and spatial distribution in Au/TiO2 nanoparticles under 45° incident light illumination at the single-particle level using a combination of photon-irradiated Kelvin probe force microscopy (KPFM) and electromagnetic field simulation. We quantitatively uncover the relationship between the local charge density and polarization angle by investigating the polarization-dependent surface photovoltage (SPV). The plasmon-induced photocatalytic activity is enhanced when the polarization direction is perpendicular to the Au/TiO2 interface.

Providing sufficient driving force for charge separation and transfer (CST) is a critical issue in photoelectrochemical (PEC) energy conversion. Normally, the driving force is derived mainly from band bending at the photoelectrode/electrolyte interface but negligible in the bulk. To boost the bulky driving force, we report a rational strategy to create effective electric field via controllable lattice distortion in the bulk of a semiconductor film. This concept is verified by the lithiation of a classic TiO2 (Li-TiO2) photoelectrode, which leads to significant distortion of the TiO6 unit cells in the bulk with well-aligned dipole moment. A remarkable internal built-in electric field of ~2.1 × 102 V m−1 throughout the Li-TiO2 film is created to provide strong driving force for bulky CST. The photoelectrode demonstrates an over 750% improvement of photocurrent density and 100 mV negative shift of onset potential upon the lithiation compared to that of pristine TiO2 film., The driving force for charge transfer in photoelectrochemical systems is typically derived from band bending at a surface-electrolyte interface. In this work, battery-type lithiation of TiO2 generates a built-in electric field in the bulk material, giving a 750% enhancement in photocurrent density.

A 0D-1D direct Z-scheme heterojunction consisting of black phosphorus quantum dots (BPQDs) anchored onto WO3 nanowires was well designed. Kelvin probe force microscopy studies provide direct evidence for charge transfer and separation between BPQDs and WO3 in a single nanowire, confirming the Z-scheme model. The BPQD-WO3 heterojunction displays excellent performance of photocatalytic reduction of CO2, exhibiting not only highly efficient carbon monoxide solar fuel conversion, but also a significant amount of ethylene (C2H4), a highly value-added hydrocarbon species, rarely reported in previous photocatalysis processes. Both experimental and theoretical calculations demonstrate that BPQD plays a critical role in photocatalytic formation of C2H4 from CO2.

Metal-organic frameworks (MOFs) have been intensively studied as a class of semiconductor-like materials in photocatalysis. However, band bending, which plays a crucial role in semiconductor photocatalysis, has not yet been demonstrated in MOF photocatalysts. Herein, a representative MOF, MIL-125-NH

Flucloxacillin (FLX) induces adverse liver reactions, which has been reported to be related to human leukocyte antigen (HLA)-B*57:01. In a previous study, abacavir-induced hypersensitivity was induced in HLA-B*57:01-transgenic mice (B*57:01-Tg), originally constructed by our group (Susukida et al., 2021). In this study, B*57:01-Tg mice were used to reproduce FLX-induced liver injury. However, treatment of B*57:01-Tg mice with FLX alone did not increase serum ALT levels. Immune-deficient B*57:01-Tg/PD-1

Understanding the role of surface charges in the catalytic reaction is of great importance to fundamental science in photoelectrochemistry (PEC). However, spatial heterogeneities of charge transfer sites and catalytic sites at the electrode/electrolyte interface obscures the surface reaction process. Herein, we quantified the relationship between the local catalytic current of the hydrogen evolution reaction (HER) and the surface charge density using operando spatially resolved photovoltage microscopy on the Pt/Ti array on the p-Si photoelectrode. We found that the Pt/Ti islands on the p-Si surface worked as the main charge collect areas but as the sole catalytic sites to drive the PEC hydrogen evolution. Based on the achievements of identifying the local photocurrent and photovoltage on a single Pt/Ti island, we found that the local HER current can be linearly regulated by the charge density at reactive sites by concurrently adjusting the bias potential and the spacings of the Pt/Ti islands. These results emphasize the significant impact of the surface charge density on the catalytic activity in photoelectrochemistry.

The involvement between electron transfer (ET) and catalytic reaction at the electrocatalyst surface makes the electrochemical process challenging to understand and control. Even ET process, a primary step, is still ambiguous because it is unclear how the ET process is related to the nanostructured electrocatalyst. Herein, locally enhanced ET current dominated by mass transport effect at corner and edge sites bounded by {111} facets on single Au triangular nanoplates was clearly imaged. After decoupling mass transport effect, the ET rate constant of corner sites was measured to be about 2-fold that of basal {111} plane. Further, we demonstrated that spatial heterogeneity of local inner potential differences of Au nanoplates/solution interfaces plays a key role in the ET process, supported by the linear correlation between the logarithm of rate constants and the potential differences of different sites. These results provide direct images for heterogeneous ET, which helps to understand and control the nanoscopic electrochemical process and electrode design.

All industries around the world have been greatly impacted by the 2019 COVID-19 outbreak. China’s tourism market was almost suspended. Tourism enterprises generally face difficulties in the form of low capital turnover and increased operating pressure, and the overall tourism industry is showing a downturn in its development. In this study, we construct a quasi-natural experiment with the COVID-19 pandemic in public health emergencies using a propensity score matching difference in differences model (PSM-DID) to match the treatment group of tourism enterprises and the control group of non-tourism enterprises. We empirically test that the COVID-19 pandemic has produced a more severe impact on the performance of tourism enterprises than other industries. Further analysis shows that given different enterprise equity natures, the characteristics of the board, supervision, and executive salary incentive levels, the COVID-19 pandemic has a heterogeneous impact on the operating performance of tourism enterprises.